RSLB.F Stock Overview
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in the Asia-Pacific, the Middle East, the Americas, Europe, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr8.33 |
| 52 Week High | kr9.30 |
| 52 Week Low | kr6.45 |
| Beta | 1.23 |
| 1 Month Change | 0% |
| 3 Month Change | -10.43% |
| 1 Year Change | n/a |
| 3 Year Change | -23.58% |
| 5 Year Change | -22.66% |
| Change since IPO | 278.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| RSLB.F | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | -6.1% | -3.7% |
| 1Y | n/a | -11.9% | 20.2% |
Return vs Industry: Insufficient data to determine how RSLB.F performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how RSLB.F performed against the US Market.
Price Volatility
| RSLB.F volatility | |
|---|---|
| RSLB.F Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RSLB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RSLB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 388 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in the Asia-Pacific, the Middle East, the Americas, Europe, and Africa. It develops and markets RayStation, a treatment planning system; RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information. In addition, it offers µ-RayStation, a software platform for planning and evaluation in small animal irradiation research; RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights.
RaySearch Laboratories AB (publ) Fundamentals Summary
| RSLB.F fundamental statistics | |
|---|---|
| Market cap | US$370.66m |
| Earnings (TTM) | US$7.59m |
| Revenue (TTM) | US$95.11m |
48.8x
P/E Ratio3.9x
P/S RatioIs RSLB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RSLB.F income statement (TTM) | |
|---|---|
| Revenue | kr1.02b |
| Cost of Revenue | kr106.58m |
| Gross Profit | kr915.58m |
| Other Expenses | kr834.01m |
| Earnings | kr81.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.38 |
| Gross Margin | 89.57% |
| Net Profit Margin | 7.98% |
| Debt/Equity Ratio | 0.1% |
How did RSLB.F perform over the long term?
See historical performance and comparison